Pa. cell therapy developer seeks to raise $45.1M from stock offering

09/27/2013 | American City Business Journals

Fibrocell Science, which specializes in developing autologous cell treatments, estimated it could bring in $45.1 million in a public offering of stocks expected to close next week. Proceeds will support Phase II and III trials of its azficel-T wrinkle treatment. The trials will evaluate azficel-T's efficacy in treating burn scars, acne scars and vocal cord scars.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC